BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer - The Manila Times
BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer The Manila Times
New Survey Data Exploring Patient Experiences with Endometrial Cancer Care Presented at 2026 Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer - StreetInsider
New Survey Data Exploring Patient Experiences with Endometrial Cancer Care Presented at 2026 Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer StreetInsider
New Survey Data Exploring Patient Experiences with Endometrial Cancer Care Presented at 2026 Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer - PR Newswire
New Survey Data Exploring Patient Experiences with Endometrial Cancer Care Presented at 2026 Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer PR Newswire